Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jul 15;39(7):BSR20190980.
doi: 10.1042/BSR20190980. Print 2019 Jul 31.

Cardiovascular risk of sitagliptin in treating patients with type 2 diabetes mellitus

De-Kang Zeng  1 , Qian Xiao  2 , Fa-Qi Li  2 , Yu-Zhi Tang  1 , Chao-Li Jia  3 , Xue-Wen Tang  4
Affiliations
Review

Cardiovascular risk of sitagliptin in treating patients with type 2 diabetes mellitus

De-Kang Zeng et al. Biosci Rep. .

Abstract

Patients with type 2 diabetes mellitus (T2DM) have a very high risk of cardiovascular related events, and reducing complications is an important evaluation criterion of efficacy and safety of hypoglycemic drugs. Previous studies have shown that the dipeptidyl peptidase-4 (DPP-4) inhibitors (DPP4i), such as sitagliptin, might reduce the incidence of major cardiovascular events (MACEs). However, the safety and efficacy of sitagliptin remains controversial, especially the safety for cardiovascular related events. Here, a systematic review was conducted to assess the cardiovascular safety of sitagliptin in T2DM patients. The literature research dating up to October 2018 was performed in the electronic database. The clinical trials about sitagliptin for T2DM patients were included. Two reviewers independently screened literature according to the inclusion and exclusion criteria. The primary outcome was the MACE, and the secondary outcome was all-cause mortality. Finally, 32 clinical trials composed of 16082 T2DM patients were included in this meta-analysis. The results showed that: there was no significant difference between sitagliptin group and the control group on MACE (odds ratio (OR) = 0.85, 95% confidence intervals (CIs) = 0.63-1.15), myocardial infarction (MI) (OR = 0.66, 95% CI = 0.38-1.16), stroke (OR = 0.83, 95% CI = 0.44-1.54) and mortality (OR = 0.52, 95% CI = 0.26-1.07). These results demonstrated that sitagliptin did not increase the risk of cardiovascular events in patients with T2DM.

Keywords: cardiovascular safety; sitagliptin; type 2diabetes mellitus.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no competing interests associated with the manuscript.

Figures

Figure 1
Figure 1. Flow chart of the present study
Figure 2
Figure 2. Number of patients with MACEs in two groups
(A) Meta-analysis showed the non-significant difference on this outcome; (B) funnel plots showed no potential publication bias.
Figure 3
Figure 3. Number of patients with MI in two groups
(A) Meta-analysis showed the non-significant difference on this outcome; (B) funnel plots showed no potential publication bias.
Figure 4
Figure 4. Number of patients with stroke in two groups
(A) Meta-analysis showed the non-significant difference on this outcome; (B) funnel plots showed no potential publication bias.
Figure 5
Figure 5. Number of mortality in two groups
(A) Meta-analysis showed the non-significant difference on this outcome; (B) funnel plots showed no potential publication bias.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Skovgaard R., Ploug U.J., Hunt B.. et al. (2015) Evaluating the cost of bringing people with type 2 diabetes mellitus to multiple targets of treatment in Canada. Clin. Ther. 37, 1677–168810.1016/j.clinthera.2015.05.496 - DOI - PubMed
    1. Strain W.D., Agarwal A.S. and Paldánius P.M. (2017) Individualizing treatment targets for elderly patients with type 2 diabetes: factors influencing clinical decision making in the 24-week, randomized INTERVAL study. Aging 9, 769–77710.18632/aging.101188 - DOI - PMC - PubMed
    1. Chen J., Bai S J., Li W.. et al. (2018) Urinary biomarker panel for diagnosing patients with depression and anxiety disorders. Transl. Psychiatry 8, 192.10.1038/s41398-018-0245-0 - DOI - PMC - PubMed
    1. Chen J., Xie J., Zeng L.. et al. (2019) Urinary metabolite signature in bipolar disorder patients during depressive episode. Aging 11, 1008–101810.18632/aging.101805 - DOI - PMC - PubMed
    1. Xie J., Li N., Jiang X.. et al. (2019) Short-term efficacy and safety of repaglinide versus glimepiride as augmentation of metformin in treating patients with type 2 diabetes mellitus. Diabetes Metab. Syndr. Obes. 12, 519–52610.2147/DMSO.S198154 - DOI - PMC - PubMed

MeSH terms